MBCProject_3632_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0CP-01A-11R-A034-07 | — | A | 0.875 |
| 2 | 57583139-d2d3-4b97-a616-aa96058d4682 | — | — | 0.858 |
| 3 | SRR493947 | — | cohortA1 | 0.850 |
| 4 | MBCProject_0988_T1_RNA | — | B | 0.846 |
| 5 | TCGA-3C-AALK-01A-11R-A41B-07 | — | A | 0.841 |
| 6 | TCGA-E2-A1IF-01A-11R-A144-07 | — | A | 0.841 |
| 7 | SRR35579814 | — | A | 0.838 |
| 8 | 69d9a82b-5c37-45bd-a1cf-ffe1392e84fc | — | — | 0.837 |
| 9 | 44f9e45d-d779-4865-8f10-d085d5d25447 | — | — | 0.837 |
| 10 | MBCProject_3672_T1_RNA | — | B | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |